ExonHit chosen to join the European Innovative Medicines Initiative consortium on Alzheimer’s disease
PharmaCog stands for “Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development”. It is a cross party project, cocoordinated by GlaxoSmithKline R&D and the Université de la Méditerranée, Marseille, France. It brings together top scientists from 5 small and medium size enterprises, 11 global pharmaceutical companies, 12 academic institutions; in addition, 1 patient group representing 9 countries across Europe will ensure the dissemination of PharmaCog results. The European Medicines Agency (EMA), an associated partner of the project, will share project progress and discuss the implications for drug development in Europe.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.